RET and melanoma: Eight of 11 control mice (72.7 %) showed either retroperitoneal metastasis or mediastinal adenopathies, whereas only three of nine mice (33.3 %) in the HB-19-treated group showed visceral or lung metastasis: HB-19 treatment partly prevented metastasis of melanoma cells in RET mice.